ClinicalTrials.gg
Not yet recruitingNCT07178730ADAPT-TN-IVUpdated Aug 5, 2026

NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer

A Phase 3 interventional study of Sacituzumab govitecan and Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] in Breast Cancer and Triple-negative Breast Cancer, sponsored by Women's Cancer Study Group GmbH. Not yet recruiting at 26 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Primary conditionTriple Negative Breast NeoplasmsRegistry: Breast NeoplasmsReclassifiedWhy we changed it
Registry
Breast Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Triple Negative Breast Neoplasms
Why
  1. The study's listed conditions name Triple Negative Breast Neoplasms, a narrower term within Breast Neoplasms.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Women's Cancer Study Group GmbH · Phase 3, Interventional, and Treatment

How we know · 6 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
765
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms — 11 open to participants now, 18 under way, 6 of them phase 3. sacituzumab govitecan · Triple Negative Breast Neoplasms.

Planned enrollment
3rd of 21
765 · median 138
Started
2026
with 1 other
Phase 3
6 of 21
2 open now
Primary completion
2033-03
later than 17 of 17 live
Registered
20th of 21
by date

Among the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, this one is the 3rd largest by planned enrollment, is one of 2 that started in 2026, is one of 6 in phase 3, reaches primary completion later than 17 of the 17 other live ones, and was the 20th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

11 of the 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About sacituzumab govitecan

sacituzumab govitecan: first FDA approval 2020 (TRODELVY), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing sacituzumab govitecan in Triple Negative Breast Neoplasms, or all of them as a file.
02

Study summary

TNBC is a heterogeneous disease with distinct pathological, genetic, and clinical features among subtypes. Treatment results for high-risk primary TNBC remain poor compared to other breast cancer subtypes. Preoperative chemotherapy is the standard of care for patients with stage II or III primary TNBC. Multiple lines of clinical evidence demonstrate that TNBC patients who achieve a pCR to NACT, (ypT0/is ypN0), have an excellent long-term prognosis. A meta-analysis of individual patient data confirmed a strong association of pCR after NACT with improved long-term event-free survival (EFS, hazard ratio [HR] 0.24) and overall survival (OS, HR 0.16) benefit. Taxane- and anthracycline-based neoadjuvant regimens generally result in pCR rates between 25-50% [REFs], whereas the addition of platinum increases pCR rates to approximately 50-55%.

The KEYNOTE-522 trial has demonstrated that the addition of the immune-checkpoint inhibitor PEM to anthracycline- (AC), taxane- and platinum-based NACT resulted in a significant increase in pCR rates to nearly 65%, associated with a significant reduction of recurrences (EFS, HR 0.65 at 5 years) and improvement of OS (HR 0.66). Based on these results, the KEYNOTE-522 regimen has been approved by the FDA and EMA and has become the standard of care for patients with stage II or III TNBC.

Despite this significant progress, two major questions remain unresolved which will be investigated in the ADAPT-TN-IV trial:

  1. Do all patients require the full 6 months of NACT as per KEYNOTE-522 or is there a subgroup of patients who are sufficiently treated with 12 weeks of NACT plus PEM?
  2. Can incorporation of ADCs into the KEYNOTE-522 regimen improve response and outcomes in patients without an optimal early response? The outcome of patients with residual disease after 24 weeks of NACT and PEM remains suboptimal and there is an urgent need for more effective strategies. ADCs such as SG have demonstrated superior efficacy compared to standard chemotherapy in metastatic TNBC, resulting in substantially higher response rates and improved progression-free (PFS) and OS. Combination studies of ADCs and immunotherapy in metastatic TNBC have demonstrated significant activity, suggesting possible synergistic activity It is therefore a logical next step to investigate, whether the incorporation of SG in the NACT regimen can improve pCR rates and EFS results in patients who have residual clinical disease after 12 weeks of NACT with CARBO/PAC + PEM.
Read the detailed description

The trial will have two cohorts.

COHORT I - SoC DE-ESCALATION Cohort I will include patients with clinical stage II TNBC who have achieved a cCR to 12 weeks of NACT with CARBO/ PAC, and PEM. The trial will evaluate whether these patients can be safely spared from further chemotherapy (CTx) and directly proceed to surgery.

If it is unclear whether patients have a cCR, a tumour biopsy (by ultrasound or mammography/MRI-guided) is required to confirm that there is no evidence of residual invasive disease.

After surgery, patients with a pCR (ypT0/is, ypN0) will not receive further chemotherapy, but continue otherwise on SoC treatment.

Patients with residual disease should be considered for postoperative SoC treatment, which might include further CTx (e.g., AC or AC x4) plus PEM or OLA (in patients with gBRCA mutations).

COHORT II - ADC-INTENSIFICATION (STUDY TREATMENT) vs. SoC Cohort II will include all clinical stage III-patients and stage II patients without a cCR after 12 weeks of NACT with CARBO/ PAC and PEM.

If it is unclear whether patients have a cCR, a tumour biopsy (by ultrasound or mammography/MRI-guided) is required to confirm that there is no evidence of residual invasive disease.

These patients will be randomized 1:1 to further neoadjuvant treatment in either

  • Arm 1: neoadjuvant SG+PEM, followed by surgery and pCR-dependent post-neoadjuvant SoC treatment or
  • Arm 2: SoC CTx+SoC, followed by surgery and pCR-dependent post-neoadjuvant SoC treatment
03

Conditions studied

  • Breast Cancer
  • Triple-negative Breast Cancer

Browse trials for

04

In context

Triple Negative Breast Neoplasms Reclassified

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.

This study's planned enrollment of 765 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.

Browse Triple Negative Breast Neoplasms studies →

Lead sponsor

Women's Cancer Study Group GmbH is the lead sponsor of 6 studies on the registry; 5 are open to participants now.

Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Minimal eligibility criteria to be met for registration in the clinical trial:

  1. TNBC: ER = 0%, PR = 0%, and - (i.e., immunohistochemistry [IHC] with DAKO score ≤ 1 or fluorescence in situ hybridization [FISH]-negative)
  2. or TNBC-like: ER ≤ 10% positive cells in IHC, PR \< 10% positive cells in IHC, and HER2- (i.e., IHC with DAKO score ≤ 1 or FISH negative)
  3. All patients, independent from gender
  4. ≥18 years at diagnosis
  5. confirmed unilateral, primary invasive carcinoma of the breast Note: bilateral, multicentric, or multifocal carcinoma may be included, if there is a clear target (primary) lesion, that is subject to treatment decisions and solely evaluated and documented for study purposes. Histological confirmation of all lesions as TNBC is mandatory.
  6. Clinical stage II-III at baseline
  7. No clinical evidence for distant (M0)
  8. Cognitive and language skills to complete quality of life (QoL) questionnaires

    Additional eligibility criteria to be met for assignment to cohort I or II:

  9. Completed 9-12 weeks of NACT with CARBO + PEM or PAC q1w + PEM q3w with the last dose of NACT given less than 2 weeks ago. Patients may also be considered if their NACT treatment was switched to nab-PAC due to intolerance to PAC.

    • Patients with progressive disease during taxane-CARBO treatment are allowed to participate in cohort II after consultation with sponsor, provided that at least 6-9 weeks of NACT with taxane-CARBO q1w and PEM q3w have been administered
    • Patients experiencing toxicities due to PEM, in case of or other medical reasons against PEM administration (with or without permanent discontinuation of PEM) can nevertheless be included, even if PEM will not be administered anymore. The number of patients starting the study without PEM is limited to 10%.
  10. Tumour block available for central pathology review
  11. Performance Status ≤ 1 or Index ≥ 80%
  12. Written prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented according to the local regulatory requirements
  13. The patient must be capable of giving informed consent and be willing and able to comply with the requirements and restrictions in this protocol and accessible for treatment and follow-up
  14. Laboratory requirements (female and male patients, ≤ 14 days old)

    • Neutrophils > 1.5 109/L,
    • > 100 109/L,
    • Total \< 1 x upper level of normal (),
    • ASAT (sGOT) \< 2.5 x ULN,
    • ALAT (sGPT) \< 2.5 x ULN,
    • Creatinine ≤1.5 × ULN OR clearance ≥30 mL/min for participant with creatinine levels >1.5 × institutional ULN
  15. Clinical assessments:

    - Normal (ECG) (within 42 days prior to induction treatment)

  16. Negative pregnancy test (urine or serum) within ≤ 14 days prior to registration in premenopausal patients and immediate implementation of adequate measures.

    Note: Pregnancy testing is to be repeated according to Schedule of Activities.

  17. The following age-specific requirements apply:

    • Women aged \<50 years will be considered if they have been amenorrhoeic for 12 months or more following cessation of exogenous hormonal treatments and if they have luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the site.
    • Women aged ≥ 50 years will be considered post-menopausal if they have been amenorrhoeic for 12 months or more following cessation of all exogenous hormonal treatments.
  18. Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods outlined for women of and need to discontinue HRT to allow confirmation of post-menopausal status prior to randomization/study enrolment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can participate without use of a contraceptive method.
  19. Female patients of childbearing potential who are sexually active with a non-sterilized male partner must use at least one highly effective method of contraception, presented in Table 1 (see Section 4.4.2), from the time of enrolment and must agree to continue using such precautions for 7 months after the last dose of IMP. Not all methods of contraception are highly effective. Female patients must refrain from breastfeeding while on study and for 7 months after the last dose of IMP. Complete heterosexual abstinence for the duration of the study and drug is an acceptable contraceptive method if it is line with the patient's usual lifestyle (consideration must be made to the duration of the clinical trial); however, periodic, or occasional abstinence, the rhythm method, and the withdrawal method are not acceptable.
  20. Female patients must not donate, or retrieve for their own use, ova from the time of randomization and throughout the study treatment period, and for at least 7 months after the final study drug administration. They should refrain from breastfeeding throughout this time. Preservation of ova may be considered prior to enrolment in this study.
  21. A male participant must agree to use a contraception as detailed in Appendix C of this protocol during the treatment period and for at least 7 months after the last dose of study treatment and refrain from donating sperm during this period.

Exclusion criteria

Exclusion Criteria:

  1. Known to the compounds or incorporated substances of the IMPs
  2. Prior with a disease-free survival of \< 5 years, except curatively treated basalioma of the skin or pTis of the cervix uteri
  3. Any history of invasive breast cancer
  4. Previous or concurrent treatment with cytotoxic agents for any non-oncological reason unless clarified with sponsor
  5. Concurrent treatment with other experimental drugs
  6. Participation in another interventional clinical trial with or without any , not marketed drug within 30 days or 5 half-lives of the respective drug, whichever is longer, prior to study entry. In case of other interventional trial contact Sponsor.
  7. Concurrent pregnancy: patients of or potentially childbearing partners of male patients must implement a highly effective (less than 1% failure rate) non-hormonal measures during the study treatment
  8. Breast feeding woman
  9. Reasons indicating risk of poor compliance
  10. Patients not able to consent
  11. Known polyneuropathy ≥ grade 2
  12. Severe and relevant co-morbidity that would interact with the application of cytotoxic agents or the participation in the study including recovery from major surgery, disease, known psychiatric/substance abuse disorders, acute cystitis, ischuria, and chronic kidney disease
  13. Uncontrolled infection requiring i.v. antibiotics, antivirals, or antifungals
  14. History of pneumonitis haemolytic anaemia, myocarditis, sclerosing cholangitis and exocrine pancreatic insufficiency, medical history of allogenic stem cell transplants, or solid organ transplant
  15. Active primary immunodeficiency, known (HIV) infection. Patients should be tested for HIV prior to randomization if required by local regulations or ethics committee. Patients who test positive for HIV-antibody are excluded.
  16. Active virus (HBV) or virus (HCV). In patients with a history of HBV or HCV, patients with the following detectable viral loads will be excluded.
  17. Patients who test positive for hepatitis B surface antigen (HBsAg). Patients who test positive for hepatitis B core antibody (anti-HBc) will require HBV DNA by quantitative polymerase chain reaction (PCR) for confirmation of active disease.
  18. Patients who test positive for HCV antibody will require HCV RNA by quantitative PCR for confirmation of active disease. Patients with a known history of HCV or a positive HCV antibody test will not require an HCV antibody test at enrolment and will only require HCV RNA by quantitative PCR for confirmation of active disease.
  19. Patients who received within 30 days prior to randomization.
  20. Patients who are submitted to an institution by virtue of an order of a court or a governmental authority must be excluded from participation.
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
765 participants (estimated)

Study arms

  • Other
    Cohort I (non-randomized)

    Cohort I will include patients with clinical stage II disease at baseline who have a cCR after up to 12 weeks of NACT with CARBO/PAC and PEM. After surgery, patients with a pCR (ypT0/is, ypN0) will not receive further chemotherapy (CTx) but continue on SoC treatment according to current valid treatment guidelines for breast cancer at investigator´s discretion. Patients with residual disease should be considered for postoperative SoC treatment, which may include further CTx (e.g., AC/EC x 4, q2w or q3w or Capecitabine) plus PEM or Olaparib (in patients with gBRCA mutations) according to current valid treatment guidelines for breast cancer and per investigator´s discretion.

    Drug: SoC Chemotherapy

  • Experimental
    Cohort II (randomized) - Sacituzumab govitecan + pembrolizumab (SG+PEM)

    neoadjuvant SG+PEM (4 cycles), followed by surgery and pCR-dependent post-neoadjuvant SoC treatment according to current valid treatment guidelines for breast cancer and per investigator´s discretion.

    Drug: Sacituzumab govitecan · Drug: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]

  • Active comparator
    Cohort II (randomized) - Standard-of-care chemotherapy + pembrolizumab (SoC CTx+PEM)

    SoC, e.g., AC x 4 + PEM or EC x 4 + PEM, followed by surgery and pCR-dependent post-neoadjuvant SoC treatment, e.g., AC x 4 \* PEM or EC x 4 + PEM, or Capecitabine + PEM or Olaparib (in patients with gBRCA mutations), according to current valid treatment guidelines for breast cancer and per investigator´s discretion.

    Drug: Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA] · Drug: SoC Chemotherapy

Interventions

  • SG is administered at 10 mg/kg as an intravenous (i.v.) infusion on Days 1 and 8 of a 21-day cycle. The dose of SG will be calculated based on actual weight at randomization (using weight obtained either at enrolment or on Cycle 1 Day 1) and remains constant throughout the study, unless there is a \> 10% change in body weight from baseline. Modifications to the study drug doses administered should be made for a \> 10% change in body weight from baseline and according to local and regional prescribing standards. Dose modifications for changes in body weight \< 10% may be made according to local institutional guidelines. SG is administered via i.v. infusion as described below with additional information available in the current version of the SmPC.

    Also known as: Trodelvy

  • DrugPembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA]

    Drug page: PembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Pembrolizumab 200 mg will be administered as a 30-minute i.v. infusion every 3 weeks.

    Also known as: Keytruda

  • DrugSoC Chemotherapy

    Standard of care chemotherapy as per common treatment guidelines and recommendations

    Also known as: diverse

This study also gives OlaparibStudies of OlaparibOlaparib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

07

What researchers measure

Primary outcomes

  1. Cohort I: 3-year event-free survival (EFS)

    EFS after 36 months defined as time from registration to any invasive breast cancer event, death, or secondary malignancy (same definition as iDFS) according to STEEP 2.0 criteria \[103\]

    Time frame: EFS 3 years

  2. Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to event-free survival (EFS)

    EFS after 36 months defined as time from registration to any invasive breast cancer event, death, or secondary malignancy or local progress precluding surgery in neoadjuvant treated patients

    Time frame: EFS 3 years

  3. Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pathological complete response (pCR) rates

    pCR defined as no invasive disease in breast and lymph nodes (ypT0/is, ypN0) in patients of both arms

    Time frame: EFS 3 years

Secondary outcomes

  1. clinical response after 12 weeks of neoadjuvant chemotherapy treatment (NACT)

    Clinical response measured by tumour size in mm by palpation, ultrasound, mammography, or MRI

    Time frame: 12 weeks NACT

  2. distant disease-free survival (dDFS)

    distant disease-free survival (dDFS)

    Time frame: 3 years

  3. relapse-free survival (RFS)

    relapse-free survival (RFS)

    Time frame: 3 years

  4. locoregional relapse-free survival (LRFS)

    locoregional relapse-free survival (LRFS)

    Time frame: 3 years

  5. overall survival (OS)

    OS defined as time from first diagnosis to death

    Time frame: 3 years

  6. Health-related quality of life (HRQoL) via questionnaires EORTC-QLQ-C30, version 3.0,

    Change of Health-related quality of life (HRQoL)between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort I: end of the neoadjuvant treatment, at clinical response assessment, at surgery, at start of post-neoadjuvant treatment, at cycle 3, at cycle 5, at end of post-neoadjuvant treatment, 3-monthly during follow-up

  7. Health-related quality of life (HRQoL)via questionnaires EORTC QLQ-BR42

    Change of Health-related quality of life (HRQoL)between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort I: end of the neoadjuvant treatment, at clinical response assessment, at surgery, at start of post-neoadjuvant treatment, at cycle 3, at cycle 5, at end of post-neoadjuvant treatment, 3-monthly during follow-up

  8. Health-related quality of life (HRQoL)via CANKADO active

    Change of Health-related quality of life (HRQoL)between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort I: end of the neoadjuvant treatment, at clinical response assessment, at surgery, at start of post-neoadjuvant treatment, at cycle 3, at cycle 5, at end of post-neoadjuvant treatment, 3-monthly during follow-up

  9. Health-related quality of life (HRQoL)via questionnaires EORTC-QLQ-C30, version 3.0,

    Change of Health-related quality of life (HRQoL)between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort II: end of the neoadjuvant treatment, at clinical response assessment, at cycle 3 of prolonged neoadjuvant treatment, at surgery, at start of post-neoadjuvant treatment, 3-monthly during follow-up

  10. HRQoL via questionnaires EORTC QLQ-BR42

    Change of HRQoL between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort II: end of the neoadjuvant treatment, at clinical response assessment, at cycle 3 of prolonged neoadjuvant treatment, at surgery, at start of post-neoadjuvant treatment, 3-monthly during follow-up

  11. HRQoL via CANKADO active

    Change of HRQoL between baseline, after completion of SoC neoadjuvant treatment, and on following defined timepoints:

    Time frame: Cohort II: end of the neoadjuvant treatment, at clinical response assessment, at cycle 3 of prolonged neoadjuvant treatment, at surgery, at start of post-neoadjuvant treatment, 3-monthly during follow-up

08

Study locations

26 sites
  • SLK-Kliniken Heilbronn GmbH, Klinik für Gynäkologie und Geburtshilfe
    Heilbronn, Baden-Wurttemberg 74078, Germany
  • GRN Gesundheitszentren Rhein-Neckar gGmbH, Brustzentrum Weinheim
    Weinheim, Baden-Wurttemberg 69469, Germany
  • Universitaetsklinikum Augsburg, Klinik für Frauenheilkunde und Geburtsmedizin
    Augsburg, Bavaria 86156, Germany
  • Klinikum der Universitaet Muenchen AöR, Frauenheilkunde und Geburtshilfe
    München, Bavaria 80336, Germany
    • Rachel Würstlein, Prof. Dr. · Contact
    • Nadia Harbeck, Prof. Dr. · Contact
    • Rachel Würstlein, Prof. Dr. · Principal investigator
    • Nadia Harbeck, Prof. Dr. · Sub investigator
  • Klinikum der Technischen Universitaet Muenchen (TUM Klinikum), Brustzentrum
    München, Bavaria 81675, Germany
  • Caritas-Krankenhaus St. Josef, Frauenheilkunde und Geburtshilfe
    Regensburg, Bavaria 93053, Germany
  • Haematologisch Onkologische Schwerpunktpraxis
    Würzburg, Bavaria 97080, Germany
  • Medical University Of Lausitz Carl Thiem, Frauenklinik
    Cottbus, Brandenburg 03048, Germany
  • Gesundheitszentrum Wetterau gGmbH, Gynäkologische Ambulanz
    Bad Nauheim, Hesse 61231, Germany
  • Klinikum Kassel GmbH, Klinik für Frauenheilkunde und Geburtshilfe
    Kassel, Hesse 34125, Germany
  • Gemeinschaftspraxis Frauenärzte am Bahnhofsplatz
    Hildesheim, Lower Saxony 31134, Germany
  • Universitaetsklinikum Aachen AöR, Gynäkologie und Geburtsmedizin
    Aachen, North Rhine-Westphalia 52074, Germany
    • Elmar Stickeler, Prof. Dr. · Contact
    • Elmar Stickeler, Prof. Dr. · Principal investigator
    • Tatjana Pfeil · Sub investigator
    • Brigitte Sophia Winkler, Dr. med. · Sub investigator
  • Universitaetsklinikum Bonn AöR, Senologie
    Bonn, North Rhine-Westphalia 53127, Germany
  • University Hospital Cologne AöR, Brustkrebszentrum
    Cologne, North Rhine-Westphalia 50937, Germany
  • Klinikum Dortmund gGmbH, Frauenklinik Dortmund
    Dortmund, North Rhine-Westphalia 44137, Germany
  • St.-Antonius-Hospital gGmbH, Klinik für Hämatologie und Onkologie
    Eschweiler, North Rhine-Westphalia 52249, Germany
  • Universitaetsklinikum Essen AöR Klinik für Frauenheilkunde und Geburtshilfe
    Essen, North Rhine-Westphalia 45147, Germany
  • Onkodok GmbH Onkologische Gemeinschaftspraxis
    Gütersloh, North Rhine-Westphalia 33332, Germany
  • St. Barbara-Klinik Hamm GmbH, Brustzentrum
    Hamm, North Rhine-Westphalia 59073, Germany
    • Wlodzimierz Badur, Dr. med. · Contact
    • Wlodzimierz Badur, Dr. med. · Principal investigator
    • Claudia Strunk · Sub investigator
  • Brustzentrum Rhein-Ruhr Servicegesellschaft mbH
    Mönchengladbach, North Rhine-Westphalia 41061, Germany
  • St. Franziskus-Hospital GmbH, MVZ MediaVita
    Münster, North Rhine-Westphalia 48145, Germany
  • MKS St. Paulus GmbH, Märkisches Brustzentrum
    Schwerte, North Rhine-Westphalia 58239, Germany
  • Praxisnetz Hämatologie / internistische Onkologie
    Troisdorf, North Rhine-Westphalia 53840, Germany
  • Marien-Hospital Witten, Brustzentrum
    Witten, North Rhine-Westphalia 58452, Germany
  • Klinikum Obergoeltzsch Rodewisch Frauenklinik / Brustzentrum
    Rodewisch, Saxony 08228, Germany
  • University Medical Center Hamburg-Eppendorf, Klinik und Poliklinik für Gynäkologie
    Hamburg, 20246, Germany
    • Lisa Steinhilper, Dr. med. · Contact
    • Lisa Steinhilper, Dr. med. · Principal investigator
    • Zoe Schlemmer, Dr. med. · Sub investigator
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2026; primary completion for Mar 2033, 79 months later.

Of 60 phase 3 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 103. This study's planned 79 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2025
First posted
Sep 17, 2025
StartEst.
Aug 30, 2026
Primary completionEst.
Mar 31, 2033
CompletionEst.
Mar 31, 2033
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07178730
Lead sponsor
Women's Cancer Study Group GmbH
Collaborators
Gilead Sciences
Responsible party
Sponsor
First posted
Sep 17, 2025
Start date
Aug 30, 2026 (estimated)
Primary completion
Mar 31, 2033 (estimated)
Completion
Mar 31, 2033 (estimated)
Last update
Aug 5, 2026

Study contacts

Anja Braschoß
Contact
regulatory@wsg-online.com
017682119153
Marina Mangold, Dr
Contact
marina.mangold@wsg-online.com
02161566230
Peter Schmid, PHD Dr
principal investigator · Westdeutsche Studiengruppe GmbH
Nadia Harbeck, Prof Dr
principal investigator · Breast Centre, Dept. Obstetrics & Gynaecology and CCC Munich LMU University Hospital Munich Germany
Oleg Gluz, Prof Dr
principal investigator · Breast Centre, Evang. Bethesda-Hospital Moenchengladbach Germany
Sherko Kuemmel, Prof Dr
principal investigator · Breast Centre, Kliniken Essen Mitte Essen Germany
Monika Graeser, PD Dr
principal investigator · Breast Centre, Marien-Hospital Witten Germany

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sacituzumab govitecan

Start the discussion